Role of antibody therapy in lymphoid malignancies

September 2007
British Medical Bulletin;Sep2007, Vol. 83 Issue 1, p275
Academic Journal
Introduction Over the past decade, the potential for delivering targeted therapy against malignant disease by the use of monoclonal antibodies (MoAbs) has begun to be realized. The development of human or chimeric antibodies and protein engineering to combine MoAbs with other biologically active molecules, such as radio-isotopes, toxins, chemotherapy and cytokines, has made available a new range of agents with clinical activity. Discussion This article will review the requirements and strategies for successful MoAb therapy and the clinical experience in a range of lymphoid malignancies. On the basis of substantial experience of antibodies, such as rituximab and alemtuzumab, as single agents, there is now evidence from randomized trials that the addition of antibodies to chemotherapy improves efficacy and prolongs progression free and overall survival for patients with follicular and diffuse large B-cell lymphomas. Conclusion The trials of the next decade will address issues such as the optimal strategies and timing for clinical use, the role of radio- and immuno-conjugates and, finally, what other potential molecules, such as those influencing cell growth and death, may be targeted.


Related Articles

  • Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements. Ladjemi, Maha Zohra // Frontiers in Oncology;Nov2012, Vol. 2, p1 

    Since the discovery of tumor-associated antigens (TAAs), researchers have tried to develop immune-based anti-cancer therapies. Thanks to their specificity, monoclonal antibodies (mAbs) offer the major advantage to induce fewer side effects than those caused by nonspecific conventional treatments...

  • Bevacizumab: A Review of its Use in Metastatic Colorectal Cancer. McCormack, Paul L.; Keam, Susan J. // Drugs;2008, Vol. 68 Issue 4, p487 

    Bevacizumab (Avastin) is a recombinant, humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to inhibit VEGF function in vascular endothelial cells and thereby inhibit tumour angiogenesis, upon which solid tumours depend for growth and metastasis.The...

  • Monoclonal Antibodies in Cancer Treatment: A Review of Recent Progress. Alpaugh, K.; von Mehren, M. // BioDrugs;1999, Vol. 12 Issue 3, p209 

    Research advances and promising clinical outcomes with immunotherapeutics has led to a resurgence of incorporating monoclonal antibodies in cancer treatment. Unconjugated, conjugated and multi-target constructs are emerging as a conventional form of therapy along with the classical trio of...

  • Inhibition of signaling via erbB-receptors by antibodies that target the Lewis Y-antigen. Waxenecker, G.; Klinger, M.; Farhan, H.; Freissmuth, M.; Himmler, G.; Janzek, E.; Mudde, G. C.; Loibner, H. // Cancer Cell International;2004 Supplement 1, Vol. 4, pS23 

    The article determines whether the anti-LeY antibodies IGN311 and its murine parent version ABL 364 influence the signaling in tumor cells via inhibition of growth factor receptor functions. IGN311 is a humanized monoclonal IgG1 antibody that binds to the Lewis Y (LeY) carbohydrate overexpressed...

  • A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12. Klinke,II., David J. // Molecular Cancer;2010, Vol. 9, p242 

    Monoclonal antibodies represent some of the most promising molecular targeted immunotherapies. However, understanding mechanisms by which tumors evade elimination by the immune system of the host presents a significant challenge for developing effective cancer immunotherapies. The interaction of...

  • Prognostic And Predictive Value Of c-erbB2 Overexpression In Osteogenic Sarcoma. Gupta, Nalini; Vasishta, Rakesh Kumar; Kakkar, Nandita; Sharma, S.C. // Internet Journal of Oncology;2005, Vol. 3 Issue 1, p2 

    Introduction: Osteogenic sarcoma is a highly malignant tumor of the bone, seen between 10-30 years of age. The over expression of c-erbB-2 proto-oncogene has been correlated with early metastasis and poor survival rate in various human tumors. There are very few reports in the literature...

  • Ramucirumab Conveys Survival Beneit in NSCLC.  // Personalized Medicine in Oncology;Sep2014, Vol. 3 Issue 6, p344 

    No abstract available.

  • The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. Bauerschlag, Dirk O.; Schem, Christian; Weigel, Marion T.; von Kaisenberg, Constantin; Strauss, Alexander; Bauknecht, Thomas; Maass, Nicolai; Meinhold-Heerlein, Ivo // Journal of Cancer Research & Clinical Oncology;Jan2010, Vol. 136 Issue 1, p79 

    In advanced ovarian cancers (OCs), p53 mutations are frequently observed. The objective of this study was to explore the value of the p53 mutational status, using four different techniques, in advanced OC patients as a predictive marker for responsiveness to platinum-based chemotherapy. One...

  • First-Line Treatment of Metastatic Colorectal Cancer: Focus on Cetuximab in Combination with Chemotherapy. Balko, Allison L.; Black, Esther P.; Balko, Justin M. // Clinical Medicine Reviews in Oncology;Dec2010, Issue 2, p319 

    Metastatic colorectal cancer (mCRC) is primarily treated with cytotoxic chemotherapy. However, limitations in efficacy and tolerability clearly exist with the use of these agents. Molecularly targeted agents offer alternatives to chemotherapy or in many cases, can be used in combination with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics